Puretech Health/£PRTC
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Puretech Health
PureTech Health, trading under the ticker PRTC, is a biotechnology company focused on discovering, developing, and commercializing highly differentiated medicines for devastating diseases. Operating within the healthcare sector, the company leverages its deep expertise in the understanding of disease physiology to advance a pipeline of novel therapies addressing serious medical conditions. Founded in 2015, PureTech Health engages in groundbreaking translational research that bridges the gap between innovative biological insights and potential impactful therapies.
Ticker
£PRTC
Sector
Primary listing
LSE
Industry
Biotechnology
Headquarters
Employees
56
ISIN
GB00BY2Z0H74
Website
Puretech Health Metrics
BasicAdvanced
£306M
8.19
£0.16
0.90
-
Price and volume
Market cap
£306M
Beta
0.9
52-week high
£2.17
52-week low
£1.00
Average daily volume
350K
Financial strength
Current ratio
9.333
Quick ratio
9.186
Long term debt to equity
37.127
Total debt to equity
40.59
Interest coverage (TTM)
-13.54%
Profitability
EBITDA (TTM)
-99.331
Gross margin (TTM)
-1,333.89%
Net profit margin (TTM)
1,108.33%
Operating margin (TTM)
-2,814.19%
Effective tax rate (TTM)
-16.86%
Revenue per employee (TTM)
£66,680
Management effectiveness
Return on assets (TTM)
-13.10%
Return on equity (TTM)
6.41%
Valuation
Price to earnings (TTM)
8.188
Price to revenue (TTM)
90.627
Price to book
0.73
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-3.256
Free cash flow yield (TTM)
-30.71%
Free cash flow per share (TTM)
-39.13%
Growth
Revenue change (TTM)
44.98%
Earnings per share change (TTM)
-187.50%
3-year revenue growth (CAGR)
-34.76%
10-year revenue growth (CAGR)
8.07%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
-8.49%
What the Analysts think about Puretech Health
Analyst ratings (Buy, Hold, Sell) for Puretech Health stock.
Bulls say / Bears say
PureTech Health's wholly owned program, deupirfenidone (LYT-100), achieved primary and key secondary endpoints in the ELEVATE IPF Phase 2b trial, demonstrating its potential to slow lung function decline in idiopathic pulmonary fibrosis patients. (businesswire.com)
The FDA granted Fast Track Designation to PureTech's LYT-200 for the treatment of acute myeloid leukemia, potentially expediting its development and review process. (businesswire.com)
Investment analysts at Leerink Partners initiated coverage on PureTech Health with an 'outperform' rating and a $45.00 price target, indicating strong confidence in the company's growth prospects. (marketbeat.com)
PureTech Health's stock price hit a 52-week low at $18.19 amid a broader market downturn, reflecting potential investor concerns. (investing.com)
The company reported a debt-to-equity ratio of 45.82, which may raise concerns about its financial leverage and risk profile. (defenseworld.net)
PureTech Health's stock has experienced significant volatility, with a 14.6% increase on April 14, 2025, followed by a 3.5% rise on March 25, 2025, indicating potential instability in investor sentiment. (defenseworld.net, defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Puretech Health Financial Performance
Revenues and expenses
Puretech Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Puretech Health stock?
Puretech Health (PRTC) has a market cap of £306M as of June 20, 2025.
What is the P/E ratio for Puretech Health stock?
The price to earnings (P/E) ratio for Puretech Health (PRTC) stock is 8.19 as of June 20, 2025.
Does Puretech Health stock pay dividends?
No, Puretech Health (PRTC) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Puretech Health dividend payment date?
Puretech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for Puretech Health?
Puretech Health (PRTC) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.